Nalmefene
Impulse Control Disorders
University Hospital, Clermont-FerrandSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Impulse Control Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
carbidopa Sandoz | Phase 4 | BB |
LEVODOPA University Hospital Bispebjerg and Frederiksberg | Phase 4 | BB |
Naltrexone University of Pennsylvania | Phase 4 | BB |
Clonidine Hospices Civils de Lyon | Phase 2 | B |
Naratriptan UMC Utrecht | Phase 4 | B |
View all 9 →
Same molecule, other indications
Nalmefene is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →